Skip to main content
ScholarsBetaWeill Cornell Medicine

Overview

Associate Professor of Clinical Medicine

Dr. Shore does research in stem cell/ bone marrow transplantation as well as hematological malignancies and melanoma. She is involved in multiple clinical trials including those of the CALGB National Cancer Clinical Trials organization. Dr. Shore has developed a novel nonmyeloablative regimen for stem cell transplantaion and has conducted Phase I/ II research on this protocol. The data from this study was chosen to be presented at the American Society of Clinical Oncology in 2004. Dr. Shore is also a member of the New York Cancer Consortium as well as a primary investigator for various pharmaceutical sponsored clinical trials.

Highlights

  1. 1
    Leukemia & lymphoma · 2021
    RRRichard R FurmanSASebastian A. MayerRNRoger N PearseJRJia Ruan+1 more →TBTsiporah B Shore
    PMID: 33586581DOISenior author1 citations

Publications

118 publications

Funding

1 grant
Completed grants (1)
  • MPI
    Hematopoietic Stem Cell Transplantation for Young Adults with Sickle Cell Disease- Clinical Coordinating Center
    National Heart, Lung, and Blood Institute · 2021–2023 · via Yale University
    U01HL128566-06

Clinical research

9 studies
Completed & closed trials (9)
  • PI
    Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)
    Incyte Corporation · IRB STUDY CLOSURE (as of 2025)
    Chronic Graft Vs. Host Disease
    NCT05544032
  • PI
    A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination With Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease
    PHASE2 · Cynata Therapeutics · IRB STUDY CLOSURE (as of 2025)
    Graft Versus Host Disease, Acute
    NCT05643638
  • PI
    A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
    PHASE3 · Angiocrine Bioscience, Inc. · IRB STUDY CLOSURE (as of 2024)
    Hodgkin Lymphoma; Non Hodgkin Lymphoma
    NCT05181540
  • PI
    Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, With Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation
    PHASE3 · AlloVir, Inc. · IRB STUDY CLOSURE (as of 2024)
    Adenovirus Infection
    NCT05179057
  • PI
    Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant
    PHASE2; PHASE3 · AlloVir, Inc. · IRB STUDY CLOSURE (as of 2024)
    Adenovirus Infection; BK Virus Infection; Cytomegalovirus Infections; Epstein-Barr Virus Infections; Human Herpes Virus-6 Infection; JC Virus Infection
    NCT04693637
  • PI
    A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 With Immunotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin.
    PHASE1; PHASE2 · Artiva Biotherapeutics, Inc. · IRB STUDY CLOSURE (as of 2024)
    Non Hodgkin Lymphoma
    NCT04673617
  • PI
    A Phase 1, Multicenter, Open-label Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
    PHASE1 · Juno Therapeutics, Inc. · IRB STUDY CLOSURE (as of 2023)
    Lymphoma Non-Hodgkin; Agressive Lymphoma; Diffuse-large B-cell Lymphoma (DLBCL)
    NCT04231747
  • PI
    AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients With Recurrent or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic Therapy
    PHASE2 · Syndax Pharmaceuticals, Inc. · CLOSED TO ACCRUAL (as of 2022)
    Chronic Graft-versus-host-disease
    NCT04710576
  • PI
    An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
    PHASE1; PHASE2 · Juno Therapeutics, Inc. · CLOSED TO ACCRUAL (as of 2022)
    Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Small Lymphocytic
    NCT03331198